Quick Takeaways
- REGN - REGENERON PHARMACEUTICALS, INC. has 23 insiders with reported activity on this page.
- Net insider value flow over the last year: -$9,402,511.
- Recent transaction rows are available for direct filing-level review.
- Info
- Portfolio
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 23 Insiders of REGENERON PHARMACEUTICALS, INC.
- Symbol
- REGN on Nasdaq
- Location
- Tarrytown, NY
What Changed
- Buy value: ; sell value: $9,402,511.
- Net share flow: <span class="text-red-600">-13,165</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$9,402,511.
Buys
$0
Shares: 0
Insiders: 0
Sells
$9,402,511
Shares: 13,165
Insiders: 5
Net
-$9,402,511
Shares: -13,165
Insiders: -5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,974 | $0 | $3,098,999 | +$3,098,999 |
| 3-6 | 0 | 9,191 | $0 | $6,303,512 | +$6,303,512 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
REGENERON PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| George D. Yancopoulos | Bd. Co-Chair, President & CSO, Director | $804,491,660 | Mixed | 31 Dec 2025 | ||
| Leonard S. Schleifer | Bd. Co-Chair, President & CEO, Director | $493,538,603 | Mixed | 31 Dec 2025 | ||
| VAGELOS P ROY | Director | $444,337,350 | Mixed | 03 Apr 2023 | ||
| Neil E. Stahl | EVP Research and Development | $43,324,609 | Mixed | 16 Dec 2024 | ||
| Andrew J. Murphy | EVP Research | $36,595,908 | Mixed | 09 Dec 2025 | ||
| Joseph J. Larosa | EVP General Counsel and Secret | $29,938,330 | Mixed | 05 Dec 2025 | ||
| George L. Sing | Director | $25,592,887 | Mixed | 02 Jan 2026 | ||
| Daniel P. van Plew | EVP & General Mgr, Industrial | $24,589,665 | Mixed | 09 Dec 2025 | ||
| Robert E. Landry | EVP Finance CFO | $22,918,280 | Mixed | 02 Feb 2024 | ||
| Christopher R. Fenimore | EVP Finance CFO | $15,475,790 | Mixed | 05 Dec 2025 | ||
| Arthur F. Ryan | Director | $13,725,235 | -$234,129 | -1.7% | Filing P/S | 01 Apr 2026 |
| Marion McCourt | EVP Commercial | $10,202,879 | Mixed | 09 Dec 2025 | ||
| Michael S. Brown | Director | $9,930,105 | Mixed | 02 Jan 2026 | ||
| Joseph L. Goldstein | Director | $5,173,843 | Mixed | 02 Jan 2026 | ||
| Christine A. Poon | Director | $4,028,389 | -$4,252,745 | -51% | Mixed | 02 Jan 2026 |
| Jason Pitofsky | SVP Controller | $3,516,873 | -$1,865,824 | -35% | Mixed | 09 Feb 2026 |
| Marc Tessier-Lavigne | Director | $2,315,367 | Mixed | 03 Jan 2023 | ||
| Bonnie L. Bassler | Director | $1,362,400 | -$1,770,000 | -57% | Filing P/S | 07 Jan 2026 |
| Huda Y. Zoghbi | Director | $1,345,370 | -$1,279,812 | -49% | Filing P/S | 19 Feb 2026 |
| N. Anthony Coles | Director | $1,322,985 | Mixed | 02 Jan 2026 | ||
| Craig B. Thompson | Director | $598,199 | Mixed | 02 Jan 2026 | ||
| Kathryn Guarini | Director | $465,437 | Mixed | 02 Jan 2026 | ||
| David P. Schenkein | Director | $465,437 | Mixed | 02 Jan 2026 |
Top shareholders of REGENERON PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
8.6%
|
9,075,153
|
$7,004,838,346 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
8.3%
|
8,741,270
|
$6,747,123,706 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
4.4%
|
4,660,808
|
$3,597,537,871 | — | 31 Dec 2025 | |
| DODGE & COX |
13F
|
Company |
4.4%
|
4,596,358
|
$3,547,790,849 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
13D/G
|
Company |
4.4%
from 13D/G
|
3,940,160
|
$3,041,292,891 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.4%
|
2,560,004
|
$1,975,990,279 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
2,519,540
|
$1,936,711,198 | — | 31 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
3.2%
|
3,359,563
|
$1,880,548,739 | -$2,703,197,470 | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.9%
|
2,010,517
|
$1,551,857,756 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.9%
|
1,949,797
|
$1,504,991,000 | — | 31 Dec 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
1.8%
|
1,934,326
|
$1,493,048,247 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.5%
|
1,591,105
|
$1,228,126,594 | — | 31 Dec 2025 | |
| Capital World Investors |
13F
|
Company |
1.3%
|
1,398,003
|
$1,079,077,052 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.3%
|
1,389,323
|
$1,072,379,189 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
1.2%
|
1,311,485
|
$1,012,295,927 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
1,157,426
|
$893,382,732 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1%
|
1,097,327
|
$846,993,812 | — | 31 Dec 2025 | |
| George D. Yancopoulos |
3/4/5
|
Bd. Co-Chair, President & CSO, Director |
—
mixed-class rows
|
1,721,022
mixed-class rows
|
$804,491,660 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.95%
|
995,710
|
$768,518,494 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.9%
|
944,933
|
$729,365,434 | — | 31 Dec 2025 | |
| Amundi |
13F
|
Individual |
0.75%
|
791,906
|
$611,248,483 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.74%
|
778,001
|
$600,515,632 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.73%
|
764,242
|
$589,896,126 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.73%
|
763,926
|
$589,651,560 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.71%
|
745,233
|
$575,222,995 | — | 31 Dec 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.71%
|
743,027
|
$573,520,247 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.63%
|
664,465
|
$512,880,599 | — | 31 Dec 2025 | |
| Leonard S. Schleifer |
3/4/5
|
Bd. Co-Chair, President & CEO, Director |
—
mixed-class rows
|
1,283,058
mixed-class rows
|
$493,538,603 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.58%
|
604,540
|
$466,626,290 | — | 31 Dec 2025 | |
| VAGELOS P ROY |
3/4/5
|
Director |
—
class O/S missing
|
467,104
|
$444,337,350 | — | 03 Apr 2023 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.53%
|
551,487
|
$425,680,385 | — | 31 Dec 2025 | |
| FIL Ltd |
13F
|
Company |
0.5%
|
529,190
|
$408,465,885 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.48%
|
499,544
|
$385,591,325 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.46%
|
478,551
|
$369,379,164 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.46%
|
478,389
|
$369,254,117 | — | 31 Dec 2025 | |
| Holocene Advisors, LP |
13F
|
Company |
0.44%
|
460,723
|
$355,618,262 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.42%
|
445,795
|
$344,049,000 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.42%
|
440,844
|
$340,274,258 | — | 31 Dec 2025 | |
| Neuberger Berman Group LLC |
13F
|
Company |
0.4%
|
422,127
|
$325,827,486 | — | 31 Dec 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.4%
|
421,229
|
$325,260,495 | — | 31 Dec 2025 | |
| Pacer Advisors, Inc. |
13F
|
Company |
0.38%
|
397,666
|
$306,946,455 | — | 31 Dec 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.38%
|
397,552
|
$306,858,462 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.36%
|
379,768
|
$293,131,526 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.35%
|
367,870
|
$284,716,336 | — | 31 Dec 2025 | |
| National Pension Service |
13F
|
Company |
0.34%
|
360,988
|
$278,635,808 | — | 31 Dec 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.33%
|
345,219
|
$266,466,000 | — | 31 Dec 2025 | |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC |
13F
|
Company |
0.33%
|
342,319
|
$264,225,767 | — | 31 Dec 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.3%
|
318,808
|
$246,215,245 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.3%
|
311,167
|
$240,180,474 | — | 31 Dec 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.28%
|
294,049
|
$226,757,451 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for REGENERON PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.56% | $77,727 | $777.27 | -100 | 17,603 | 01 Apr 2026 | Direct |
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.56% | $78,550 | $785.50 | -100 | 17,703 | 02 Mar 2026 | Direct |
| Huda Y. Zoghbi | REGN | Common Stock | Sale | -49% | $1,279,812 | $781.33 | -1,638 | 1,703 | 19 Feb 2026 | Direct |
| Huda Y. Zoghbi | REGN | Common Stock | Options Exercise | 96.2% | 1,638 | 3,341 | 19 Feb 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -67.2% | -1,638 | 800 | 19 Feb 2026 | Direct | ||
| Jason Pitofsky | REGN | Common Stock | Sale | -32.3% | $1,585,058 | $778.52 | -2,036 | 4,272 | 09 Feb 2026 | Direct |
| Jason Pitofsky | REGN | Common Stock | Options Exercise | 18.8% | 1,000 | 6,308 | 09 Feb 2026 | Direct | ||
| Jason Pitofsky | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -52.5% | -1,000 | 905 | 09 Feb 2026 | Direct | ||
| Arthur F. Ryan | REGN | Common Stock | Sale | -0.56% | $77,853 | $778.53 | -100 | 17,803 | 09 Feb 2026 | Direct |
| Bonnie L. Bassler | REGN | Common Stock | Sale | -46.8% | $1,200,000 | $800.00 | -1,500 | 1,703 | 07 Jan 2026 | Direct |
| Bonnie L. Bassler | REGN | Common Stock | Options Exercise | 88.1% | 1,500 | 3,203 | 07 Jan 2026 | Direct | ||
| Bonnie L. Bassler | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -34.4% | -1,500 | 2,861 | 07 Jan 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Common Stock | Award | 10% | 155 | 1,703 | 02 Jan 2026 | Direct | ||
| Huda Y. Zoghbi | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Craig B. Thompson | REGN | Common Stock | Award | 25% | 155 | 775 | 02 Jan 2026 | Direct | ||
| Craig B. Thompson | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| George L. Sing | REGN | Common Stock | Award | 0.5% | 155 | 31,007 | 02 Jan 2026 | Direct | ||
| George L. Sing | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Kathryn Guarini | REGN | Common Stock | Award | 34.6% | 155 | 603 | 02 Jan 2026 | Direct | ||
| Kathryn Guarini | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| David P. Schenkein | REGN | Common Stock | Award | 34.6% | 155 | 603 | 02 Jan 2026 | Direct | ||
| David P. Schenkein | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Joseph L. Goldstein | REGN | Common Stock | Award | 2.37% | 155 | 6,703 | 02 Jan 2026 | Direct | ||
| Joseph L. Goldstein | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Arthur F. Ryan | REGN | Common Stock | Award | 0.87% | 155 | 17,903 | 02 Jan 2026 | Direct | ||
| Arthur F. Ryan | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| N. Anthony Coles | REGN | Common Stock | Award | 9.94% | 155 | 1,714 | 02 Jan 2026 | Direct | ||
| N. Anthony Coles | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Michael S. Brown | REGN | Common Stock | Award | 10% | 155 | 1,703 | 02 Jan 2026 | Direct | ||
| Michael S. Brown | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Bonnie L. Bassler | REGN | Common Stock | Award | 10% | 155 | 1,703 | 02 Jan 2026 | Direct | ||
| Bonnie L. Bassler | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| Christine A. Poon | REGN | Common Stock | Award | 3.06% | 155 | 5,219 | 02 Jan 2026 | Direct | ||
| Christine A. Poon | REGN | Non-Qualified Stock Option (right to buy) | Award | 1,962 | 1,962 | 02 Jan 2026 | Direct | |||
| George D. Yancopoulos | REGN | Common Stock | Tax liability | -8.43% | -28,570 | 310,460 | 31 Dec 2025 | Direct | ||
| George D. Yancopoulos | REGN | Common Stock | Options Exercise | 9.2% | 28,570 | 339,030 | 31 Dec 2025 | Direct | ||
| George D. Yancopoulos | REGN | 2020 Performance Stock Units | Options Exercise | -4.58% | -28,570 | 595,077 | 31 Dec 2025 | Direct | ||
| Leonard S. Schleifer | REGN | Common Stock | Tax liability | -11.8% | -28,570 | 214,523 | 31 Dec 2025 | Direct | ||
| Leonard S. Schleifer | REGN | Common Stock | Options Exercise | 13.3% | 28,570 | 243,093 | 31 Dec 2025 | Direct | ||
| Leonard S. Schleifer | REGN | 2020 Performance Stock Units | Options Exercise | -4.58% | -28,570 | 595,077 | 31 Dec 2025 | Direct | ||
| George L. Sing | REGN | Common Stock | Tax liability | -16.7% | -6,188 | 30,852 | 30 Dec 2025 | Direct | ||
| George L. Sing | REGN | Common Stock | Options Exercise | 33.1% | 9,212 | 37,040 | 30 Dec 2025 | Direct | ||
| George L. Sing | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -9,212 | 0 | 30 Dec 2025 | Direct | ||
| Daniel P. van Plew | REGN | Common Stock | Tax liability | -10.5% | -2,552 | 21,673 | 09 Dec 2025 | Direct | ||
| Andrew J. Murphy | REGN | Common Stock | Tax liability | -8.12% | -4,229 | 47,833 | 09 Dec 2025 | Direct | ||
| Marion McCourt | REGN | Common Stock | Tax liability | -6.64% | -1,021 | 14,349 | 09 Dec 2025 | Direct | ||
| George D. Yancopoulos | REGN | Common Stock | Tax liability | -29.8% | -131,874 | 310,460 | 09 Dec 2025 | Direct | ||
| George D. Yancopoulos | REGN | Common Stock | Options Exercise | 49.7% | 146,815 | 442,334 | 09 Dec 2025 | Direct | ||
| George D. Yancopoulos | REGN | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -146,815 | 0 | 09 Dec 2025 | Direct | ||
| Leonard S. Schleifer | REGN | Common Stock | Tax liability | -42% | -155,145 | 214,523 | 09 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.